Bio-Path Holdings, Inc. (BPTH) Shares Up -1.4%
Bio-Path Holdings, Inc. (NASDAQ:BPTH)’s share price shot up 1.4% on Friday . The stock traded as high as $0.32 and last traded at $0.31. 440,979 shares changed hands during trading, a decline of 29% from the average session volume of 621,192 shares. The stock had previously closed at $0.32.
Several brokerages have recently weighed in on BPTH. HC Wainwright restated a “buy” rating on shares of Bio-Path Holdings in a report on Thursday, July 20th. Zacks Investment Research downgraded Bio-Path Holdings from a “buy” rating to a “hold” rating in a report on Wednesday, July 12th. Finally, ValuEngine downgraded Bio-Path Holdings from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.
The company has a 50 day moving average of $0.32 and a 200-day moving average of $0.52. The firm’s market capitalization is $30.62 million.
Bio-Path Holdings (NASDAQ:BPTH) last issued its quarterly earnings data on Thursday, August 10th. The company reported ($0.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by $0.01. Analysts predict that Bio-Path Holdings, Inc. will post ($0.08) earnings per share for the current fiscal year.
A number of large investors have recently made changes to their positions in the stock. Legal & General Group Plc increased its position in Bio-Path Holdings by 5,474.3% during the 2nd quarter. Legal & General Group Plc now owns 1,773,799 shares of the company’s stock valued at $681,000 after buying an additional 1,741,978 shares in the last quarter. HighTower Advisors LLC increased its position in Bio-Path Holdings by 0.3% during the 2nd quarter. HighTower Advisors LLC now owns 1,267,070 shares of the company’s stock valued at $492,000 after buying an additional 4,000 shares in the last quarter. Sabby Management LLC increased its position in Bio-Path Holdings by 3.5% during the 1st quarter. Sabby Management LLC now owns 687,398 shares of the company’s stock valued at $569,000 after buying an additional 23,352 shares in the last quarter. Bank of New York Mellon Corp increased its position in Bio-Path Holdings by 1.7% during the 1st quarter. Bank of New York Mellon Corp now owns 311,645 shares of the company’s stock valued at $257,000 after buying an additional 5,172 shares in the last quarter. Finally, Tower Research Capital LLC TRC acquired a new position in Bio-Path Holdings during the 1st quarter valued at about $105,000. 15.16% of the stock is currently owned by institutional investors.
About Bio-Path Holdings
Bio-Path Holdings, Inc is a clinical and preclinical stage oncology focused antisense drug development company. The Company utilizes a technology that achieves systemic delivery for target specific protein inhibition for any gene product that is over-expressed in disease. Its drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, a deoxyribonucleic acid backbone modification.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.